Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2015
For the nine months, the standalone company reported net sales of INR 609.9 million against INR 2,021.7 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 2,780.6 million against INR 579.8 million a year ago. Loss from ordinary activities before tax was INR 3,573.5 million against INR 1,137.8 million a year ago. Net loss was INR 3,573.5 million against INR 907.3 million a year ago. Basic and diluted loss per share before and after extraordinary items were INR 57.74 against INR 14.66 a year ago.